Tunghai University

Genmont Biotech Inc.

Genmont Biotech Incorporation

Ming-Shiou Jan

Wan-Hua Tsai

Wen-Ling Yeh

Yen-Wan Hsiao

Li-Jin Hsu

Ying-Chun Lai

Yi-Hsing Chen

Chang-Chi Hsieh

I-ling Hsu

Ai Shih

Chuan-Kai Chou

Wee-wei Chieng

Junko Sugawara

Shan-ju Hsu

A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount ofGMNL-133, an effective amount ofGMNL-89, and a pharmaceutically acceptable carrier, wherein theGMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and theGMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Method for improving an effect of chemotherapeutic drug of gemcitabine on inhibiting pancreatic cancer and improving side effect of chemotherapeutic drug of Gemcitabine

The present invention relates to a probiotic composition for preventing, improving or alleviating pancreatic cancer and a method for preventing, improving or alleviating the pancreatic cancer and its complications using the probiotic composition. The probiotic composition, which is consisted of specific strains and specific ratio ofto, can significantly improve or alleviate various symptomatic indicators and severity of pancreatic cancer, thereby being applied on a method for preventing, improving or alleviating the pancreatic cancer and its complications using an oral composition including thestrains.

Probiotic composition for preventing, improving or alleviating pancreatic cancer and application thereof

This present invention relates to a screening method for rapidly identifying the hybridomas upon cell size and the expression of an exogenous label such as fluorescence labeling. This method of this present invention can largely shortens the time cost for antibody development by saving the time period with comparison of traditional methods using cell culture with media such as HAT medium.

Screening method for rapid identification of hybridomas

Growing community of inventors

Taichung, Taiwan

Ming-Shiou Jan